Genetic and Screening Services M&A update, 14–28 September 2026
This bi-weekly update tracks share-price moves, company announcements and M&A activity across Genetic and Screening Services for September 14–28, 2026, for operators, acquirers and advisors tracking regulatory and clinical evidence catalysts in the sector.
For information only. Not an appraisal or a fairness opinion.
The deeper read: Genetic and Screening Services Sector Outlook — September 2026
Key figures
- Sector median move
- +7.4%
- vs S&P 500 +0.8%
- GRAIL two-week move
- +75.6%
- includes +33.7% single-day move
- Natera two-week move
- +20.5%
- MRD data and Japan approval
- Materiality bar
- +11.2%
- sector-relative threshold
Read the report
1 / 7 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › GENETIC AND SCREENING SERVICES
Executive summary
Across September 14–28, 2026, regulatory and clinical evidence drove the period's pricing: 9 of 13 covered names rose, with a +7.4% median move against +0.8% for the S&P 500. GRAIL Inc. led at +75.6% on a favorable FDA advisory panel vote for Galleri, and Natera, Inc. gained +20.5% on new MRD data and a Japanese companion diagnostic approval. No new precedent transactions were recorded; the only ownership change was Veracyte, Inc. adding a urinary tumor DNA testing platform.
Key findings
- 9 of 13 covered names rose; median move was +7.4% vs +0.8% for the S&P 500.
- GRAIL surged +75.6% on a favorable FDA advisory panel vote for Galleri.
- Natera gained +20.5% on new MRD data and a Japanese companion diagnostic approval.
- No new M&A precedents were added; Veracyte added a urinary tumor DNA platform.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › GENETIC AND SCREENING SERVICES
This cover page introduces the bi-weekly update on Genetic and Screening Services industry events and M&A for September 14–28, 2026.
We open this bi-weekly update on Genetic and Screening Services, covering what changed, who moved and why, what transacted, and what it means for the two weeks ended September 28, 2026. Use this as the roadmap for the pages that follow.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › GENETIC AND SCREENING SERVICES Evidence and Approvals Did the Repricing, Not Transactions This update covers what moved, what companies announced and what the transaction record showed across Genetic and Screening Services from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Genetic and Screening Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
The Regulatory and Evidence Calendar Carried the Period
This page summarizes the two-week period's biggest takeaway: regulatory and clinical evidence, not deals, drove the market.
We start with the headline: across 13 covered names, the regulatory and evidence calendar carried the period rather than the deal calendar. Nine of thirteen names rose, with a +7.4% median move against +0.8% for the S&P 500. That gap tells us where the market is willing to pay up right now, so we use this page to set the frame for everything that follows.
Everything on this page
THE BI-WEEKLY BOTTOM LINE The Regulatory and Evidence Calendar Carried the Period The two-week period in one page · 13 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Genetic and Screening Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 9 of 13 Covered Names Rose over the Two-Week Period The median move was +7.4%, ahead of the S&P 500 at +0.8%. The gains clustered in names that had a regulatory or clinical evidence milestone inside the window. 2 A Favorable FDA Panel Vote Put GRAIL at the Top of the Board GRAIL Inc. (GRAL) finished the period +75.6%, including +33.7% on Sep 21, the day Reuters reported that FDA staff reviewers raised no major concerns on the Galleri blood test. The advisory committee voted in favor of approval on Sep 23. 3 Natera Paired New MRD Data with a New Market Approval Natera, Inc. (NTRA) gained +20.5% over the two-week period, following the Sep 18 presentation of the largest MRD study in lung cancer and Japanese approval of Signatera as a companion diagnostic in muscle-invasive bladder cancer on Sep 22. 4 Buyers Held While Operators Built Menu and Capacity No material sector transactions were announced during the period, against a trailing record of 28 precedent transactions. The only ownership change disclosed in the window was Veracyte, Inc. (VCYT) adding a urinary tumor DNA testing platform on Sep 14. +75.6% Best mover — GRAIL Inc. (GRAL) worst: PRE -5.6% · 9 up / 4 down of 13 covered +7.4% Sector median two-week return vs S&P 500 +0.8%
- 03PUBLIC MARKET MOVERS
Approvals and Clinical Evidence Drove the Period's Largest Gains
This page ranks the period's largest share-price moves and ties the biggest gains to regulatory or clinical evidence events.
We show the period's largest moves, with a sector median of +7.4% against +0.8% for the S&P 500 and a materiality bar of +11.2% on a sector-relative basis. GRAIL Inc. led the board at +75.6%, including a +33.7% single-day move tied to advisory-panel news, while Natera, Inc. added +20.5% around new MRD data and a Japanese approval. We read these as evidence-linked moves rather than asserted causation, so the takeaway is that milestones — not transactions — reset prices this period.
Everything on this page
PUBLIC MARKET MOVERS Approvals and Clinical Evidence Drove the Period's Largest Gains Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +7.4% · S&P 500 +0.8% · materiality bar ±11.2% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Genetic and Screening Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +7.4% GRAIL Inc. (GRAL) +75.6% Shares moved following the Sep 21 Reuters report that FDA staff reviewers flagged no major concerns on the Galleri multi-cancer test, and the company's Sep 23 announcement of a favorable advisory committee vote on approval. Regulatory milestones still reprice pre-coverage screening assets faster than volume growth does. COMPANY-SPECIFIC Natera, Inc. (NTRA) +20.5% Shares rose over the period following two Signatera announcements: the largest MRD study in lung cancer, presented Sep 18, and Japanese regulatory approval as a companion diagnostic in muscle-invasive bladder cancer on Sep 22. Proprietary evidence plus a new reimbursed indication is the combination this market pays for. COMPANY-SPECIFIC OraSure Technologies, Inc. (OSUR) +17.2% No notable in-window news was identified that clearly explains the move. The gain of +17.2% ran ahead of the sector median of +7.4%. Discount-tier names carry the most torque when the group's evidence flow turns positive. UNEXPLAINED Prenetics Global Limited (PRE) -5.6% No notable in-window news was identified that clearly explains the move. The decline of -5.6% sat against a sector median of +7.4%. Direction was not uniform: 4 of 13 covered names finished the two-week period lower. UNEXPLAINED
- 04MAJOR NEWS & INDUSTRY CATALYSTS
Companies Spent the Period Building Evidence, Capacity and Menu Depth
This page lists the two-week period's highest-impact company announcements and explains why each matters.
We walk through the period's highest-impact events, each linked back to the filing or article it came from. Natera, Inc. paired new MRD data in lung cancer with a Japanese companion diagnostic approval for Signatera, and Veracyte, Inc. added a urinary tumor DNA testing platform. These are the building blocks — evidence, capacity and menu depth — that the market rewarded this period.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS Companies Spent the Period Building Evidence, Capacity and Menu Depth The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Genetic and Screening Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 23 · NEWS · PRNewsWire GRAIL wins a favorable FDA advisory committee vote on its Galleri multi-cancer early detection test A panel vote is the gate that opens the coverage and guideline path for a screening test. For pre-coverage screening assets, the regulatory calendar is the valuation calendar. Sep 22 · NEWS · PRNewsWire Castle Biosciences to open a new laboratory facility in Scottsdale to support growing test volumes Capacity added ahead of accessioned volume is a statement about expected paid volume, and it is also where cost per test falls as automation absorbs fixed costs. Capacity decisions signal which operators expect volume to be reimbursed, not just billed. Sep 22 · NEWS · Business Wire Natera's Signatera approved in Japan as a companion diagnostic in muscle-invasive bladder cancer A companion diagnostic approval in a new market converts an existing assay into new reimbursed volume without a new platform build. It is the longitudinal franchise argument in practice. Geographic and indication expansion on a proven assay is the cheapest growth in this sector. Sep 18 · NEWS · Business Wire Natera presents the largest MRD study in lung cancer, showing prognostic value for Signatera Proprietary prospective evidence is what competitors must replicate and what payers and guideline bodies read before coverage widens. This is the evidence layer beneath ASP realisation. Clinical utility data in a large indication is the asset buyers underwrite most confidently. Sep 16 · NEWS · GlobeNewsWire Myriad Genetics promotes a commercial leader to Executive Vice President – Commercial Commercial leadership is where pull-through, payer contracting and sales productivity inside a narrow specialty are owned. The appointment signals where the company is putting its emphasis. In molecular testing, commercial execution is a value driver, not a support function. Sep 14 · NEWS · GlobeNewsWire Veracyte acquires a urinary tumor DNA testing platform, extending its urology diagnostics menu The only ownership change disclosed in the window was a menu extension rather than a scale purchase, which fits a market where buyers add indication depth around an existing call point. Menu depth chosen deliberately, not breadth for its own sake, is how the record shows buyers moving.
- 05M&A & STRATEGIC ACTIVITY
No New Precedents This Period; The Only Ownership Move Was a Menu Extension
This page reports that no new precedent transactions were announced in the period, against a trailing record of 28 recorded deals.
We confirm that no new precedent transactions were announced across the two-week period, leaving the reference set at 28 recorded deals. The only ownership move on record was Veracyte, Inc. adding a urinary tumor DNA testing platform on September 14. For buyers and advisors, that means the comparable set moved through trading rather than through new deal evidence this period.
Everything on this page
M&A & STRATEGIC ACTIVITY No New Precedents This Period; The Only Ownership Move Was a Menu Extension September 14–28, 2026 · precedent transactions: 28 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Genetic and Screening Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The only ownership change disclosed in the window was Veracyte, Inc. (VCYT) adding a urinary tumor DNA testing platform to its urology portfolio on Sep 14. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 28 Recorded precedent transactions the reference set buyers and sellers price against
- 06WHAT IT MEANS
What the Period Changes for Operators, Buyers and Advisors
This page translates the period's evidence and pricing into implications for operators, buyers and advisors.
We bring the period together for the people who act on it: operators saw the market pay for milestones that convert into paid volume, acquirers watched the reference set reprice through trading rather than new deals, and advisors should lead conversations with where an asset sits on the reimbursement clock. These are our reads of the recorded evidence, not recommendations, so we use them to frame next steps rather than dictate them.
Everything on this page
WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Genetic and Screening Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 3.1x 11 companies in the study 3 valuation tiers Standing thesis: Genetic and Screening Services Split Between Reference Testing and Adjacent Models FOR OWNERS & OPERATORS The Market Paid for Milestones That Convert into Paid Volume Companies in the space traded higher over the two-week period, and the strongest moves sat with names that put a regulatory or clinical evidence milestone on the board. FOR ACQUIRERS The Reference Set Moved on Trading, Not on New Precedents With no transactions added in the window, the comparable set repriced through the market rather than through deals. FOR ADVISORS Lead with Where an Asset Sits on the Reimbursement Clock The period's evidence is regulatory and clinical: GRAIL Inc. (GRAL) on a favorable advisory committee vote, Natera, Inc. (NTRA) on Japanese companion diagnostic approval and new MRD data, and Veracyte, Inc. (VCYT) buying urology menu depth.
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
This page explains the sources behind the update's figures and how driver attributions are read.
We show our work here: every figure in this update ties back to the filings and publisher-sourced news recorded across the window, with market data current through September 28, 2026. Driver attributions use calibrated language because they reflect our reads of the recorded evidence rather than asserted causation. Use this page to trace any figure back to its source before acting on it.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Genetic and Screening Services Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. No covered name fell below the floor in this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T171045Z_539_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: prnewswire.com · businesswire.com · globenewswire.com
Sources and methodology
This update covers Genetic and Screening Services over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 13 listed companies whose core business is Genetic and Screening Services under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Celcuity Inc. (CELC), Castle Biosciences, Inc. (CSTL), Quest Diagnostics Incorporated (DGX), Fulgent Genetics, Inc. (FLGT), Guardant Health, Inc. (GH), GRAIL Inc. (GRAL), Myriad Genetics, Inc. (MYGN), Natera, Inc. (NTRA), OraSure Technologies, Inc. (OSUR), Prenetics Global Limited (PRE), Personalis, Inc. (PSNL), Veracyte, Inc. (VCYT), GeneDx Holdings Corp. (WGS). No covered name fell below the floor in this window.
Window and company universe
This update covers Genetic and Screening Services over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 13 listed companies whose core business is Genetic and Screening Services under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Celcuity Inc. (CELC), Castle Biosciences, Inc. (CSTL), Quest Diagnostics Incorporated (DGX), Fulgent Genetics, Inc. (FLGT), Guardant Health, Inc. (GH), GRAIL Inc. (GRAL), Myriad Genetics, Inc. (MYGN), Natera, Inc. (NTRA), OraSure Technologies, Inc. (OSUR), Prenetics Global Limited (PRE), Personalis, Inc. (PSNL), Veracyte, Inc. (VCYT), GeneDx Holdings Corp. (WGS). No covered name fell below the floor in this window.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 28 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
Sources linked in the report
- +75.6% (prnewswire.com)
- +20.5% (businesswire.com)
- +17.2% (defenseworld.net)
- -5.6% (prnewswire.com)
- Castle Biosciences to open a new laboratory facility in Scottsdale to (prnewswire.com)
- Natera's Signatera approved in Japan as a companion diagnostic in (businesswire.com)
- Myriad Genetics promotes a commercial leader to Executive Vice President – (globenewswire.com)
- Veracyte acquires a urinary tumor DNA testing platform, extending its (globenewswire.com)
- prnewswire.com (prnewswire.com)
- globenewswire.com (globenewswire.com)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Outlook · 29 September 2026Genetic and Screening Services Sector Outlook — September 2026
- M&A Update · 29 September 2026Health Care Data and Analytics M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Health Care Data and Analytics Sector Outlook — September 2026
- M&A Update · 29 September 2026Health Care Distributors M&A update, 14–28 September 2026
Want this analysis for a company in Genetic and Screening Services?
Company valuation reports run the same method against a single business — public or private.
